Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CohBar Inc CWBR

Healthcare Biotechnology
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to... see more

Recent & Breaking News (GREY:CWBR)

CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)

Business Wire November 27, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FRGI, CWBR, SCU

PR Newswire September 20, 2023

COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR

Business Wire September 19, 2023

CohBar Reports Second Quarter 2023 Financial Results

GlobeNewswire August 14, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WTT, CWBR, DM

PR Newswire July 17, 2023

Moore Kuehn Encourages CWBR, KDNY, GHL, and DM Investors to Contact Law Firm

PR Newswire July 17, 2023

IMPORTANT ALERT: Halper Sadeh LLC Investigates PDCE, CWBR, EMAN, HMPT

PR Newswire June 29, 2023

IMPORTANT ALERT: Halper Sadeh LLC Investigates GHL, CWBR, WTT, AAIC

PR Newswire June 22, 2023

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CWBR, FOCS, PTRS, ARNC

PR Newswire June 17, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CIR, PDCE, CWBR, GHL

PR Newswire June 5, 2023

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

GlobeNewswire June 5, 2023

COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR

Business Wire May 30, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRNA, AAIC, CWBR, EMBK

PR Newswire May 30, 2023

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 30, 2023

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating CohBar, Inc. Merger

Newsfile May 25, 2023

Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.

PR Newswire May 24, 2023

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CohBar, Inc. (CWBR)

Newsfile May 23, 2023

CWBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of CohBar, Inc. Is Fair to Shareholders

Business Wire May 23, 2023

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

GlobeNewswire May 23, 2023

CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire November 8, 2022